Page 443 - Best Practice Oral Presentation SP Sharing2025

I27

The Effect of intravenous Ascorbic acid combined with

intravenous tranexamic acid in Anemia of Hemodialysis patients,

A Randomized Controlled Trial.

Theerapun Boonsayomphu, M.D. , Varitsara Sakthaipatthana B.Pharm. ,
1
1
1
Suchitta Sittimart R.N. , et al.
โรงพยาบาลบุรีรัมย์ เขตสุขภาพที่ 9
ประเภท วิชาการ

ความสำคัญของปัญหาวิจัย

Anemia in hemodialysis patients is associated with adverse outcomes, including
increased mortality and prolonged hospitalizations. Intravenous ascorbic acid has been shown

to enhance hemoglobin levels and transferrin saturation due to its antioxidant properties.

Additionally, low-dose tranexamic acid may improve hemoglobin levels by inhibiting
fibrinolysis and enhancing platelet function. This study evaluates the efficacy of combined

intravenous ascorbic acid and tranexamic acid in improving hemoglobin levels compared to

ascorbic acid monotherapy.

วัตถุประสงค์การศึกษา

The primary endpoints were mean values and differences in mean values in iron study
parameters and hemoglobin levels. Secondary endpoints comprised intact parathyroid

hormone (iPTH), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and adverse
events, assessed at baseline and months 1, 2, 4, and 6.

วิธีการศึกษา
This randomized, prospective, open-label clinical trial enrolled 50 patients with end-

stage renal disease (ESRD) undergoing thrice-weekly hemodialysis. Anemia of hemodialysis was

defined as hemoglobin ≤ 11 g/dL, serum ferritin > 500 ng/mL, and transferrin saturation (TSAT)
≥ 40%. Participants were assigned to either the treatment group, receiving 500 mg of

intravenous ascorbic acid with tranexamic acid (5 mg/kg/hr) during the final hour of
hemodialysis, or the control group, receiving 500 mg of intravenous ascorbic acid with saline.

The primary endpoints were mean values and differences in mean values in iron study

parameters and hemoglobin levels. Secondary endpoints comprised intact parathyroid
hormone (iPTH), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and adverse

events, assessed at baseline and months 1, 2, 4, and 6.